Ratings by Citi (Eric Joseph)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/8/2026 | Arrowhead Pharma | ARWR | New Coverage | Buy (N/A) |
86.49 (85.61) |
-1.02% | Details | |
| 8/13/2026 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2026 | BridgeBio Pharma | BBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 7/16/2026 | BridgeBio Pharma | BBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 7/16/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 7/9/2026 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2026 | PTC Therapeutics | PTCT | Upgrade | Buy (Neutral) |
70.87 (69.20) |
-2.36% | Details | |
| 5/18/2026 | Cytokinetics | CYTK | New Coverage | Buy (N/A) |
75.85 (75.44) |
-0.54% | Details | |
| 5/18/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Buy (N/A) |
74.23 (56.69) |
-23.63% | Details | |
| 5/18/2026 | BridgeBio Pharma | BBIO | New Coverage | Neutral (N/A) |
66.13 (74.68) |
12.93% | Details | |
| 5/18/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Buy (N/A) |
51.81 (65.06) |
25.57% | Details | |
| 5/18/2026 | Ascendis Pharma | ASND | New Coverage | Buy (N/A) |
240.50 (268.81) |
11.77% | Details | |
| 5/18/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Buy (N/A) |
286.98 (261.17) |
-8.99% | Details |
